Medical devices; exception from general requirements for informed consent. Interim final rule.
The Food and Drug Administration (FDA) is issuing this interim final rule to amend its regulations to establish a new exception from the general requirements for informed consent, to permit the use of investigational in vitro diagnostic devices to identify chemical, biological, radiological, or nuclear agents without informed consent in certain circumstances. The agency is taking this action because it is concerned that, during a potential terrorism event or other potential public health emergency, delaying the testing of specimens to obtain informed consent may threaten the life of the subject. In many instances, there may also be others who have been exposed to, or who may be at risk of exposure to, a dangerous chemical, biological, radiological, or nuclear agent, thus necessitating identification of the agent as soon as possible. FDA is creating this exception to help ensure that individuals who may have been exposed to a chemical, biological, radiological, or nuclear agent are able to benefit from the timely use of the most appropriate diagnostic devices, including those that are investigational.
D018795:Device Approval / Q000331:legislation & jurisprudence; D019719:Diagnostic Equipment; D004189:Disaster Planning / Q000331:legislation & jurisprudence*; D006801:Humans; D066298:In Vitro Techniques; D007258:Informed Consent / Q000331:legislation & jurisprudence*; D011634:Public Health / Q000331:legislation & jurisprudence; D023481:Terrorism / Q000331:legislation & jurisprudence*; D035703:Therapies, Investigational; D014481:United States; D014486:United States Food and Drug Administration